**EXTRAWELL PHARMACEUTICAL HOLDINGS LIMITED**

**精優藥業控股有限公司***

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 00858)**

# CHANGE OF BUILDING NAME OF HEAD OFFICE AND PRINCIPAL PLACE OF BUSINESS IN HONG KONG

The board of directors (the "**Board**") of Extrawell Pharmaceutical Holdings Limited (the "**Company**") hereby announces that the building name of the head office and principal place of business of the Company in Hong Kong will be changed from "Devon House" to "FWD Tower" with effect from 1 January 2026 (the "**Change of Building Name**"). Accordingly, the head office and principal place of business of the Company in Hong Kong will be updated with effect from 1 January 2026 as

Suites 2206–08, 22/F., FWD Tower, Taikoo Place, 979 King's Road, Quarry Bay, Hong Kong

Save for the Change of Building Name, the physical location of the head office and principal place of business of the Company in Hong Kong remains unchanged.

By order of the Board
**Extrawell Pharmaceutical Holdings Limited**
**Xie Yi**
*Chairman*

Hong Kong, 31 December 2025

*As at the date of this announcement, the executive directors are Dr. Xie Yi, Mr. Cheng Yong, Dr. Lou Yi, Ms. Wong Sau Kuen and Dr. Guo Yi, and the independent non-executive directors are Mr. Fang Lin Hu, Ms. Jin Song and Dr. Zeng Li.*

* *For identification purpose only*